Navigation Links
Intercept Pharmaceuticals Reports Second Quarter 2013 Financial Results
Date:8/13/2013

NEW YORK, Aug. 13, 2013 /PRNewswire/ -- Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today reported financial results for the quarter and six months ended June 30, 2013 and announced presentations at an upcoming medical conference and upcoming investor conferences.

Second Quarter 2013 Financial ResultsResults of OperationsSix Months Ended June 30, 2013

For the six months ended June 30, 2013, Intercept reported a net loss of $23.7 million, or $1.41 per share, compared to a net loss of $9.3 million, or $2.78 per share, for the six months ended June 30, 2012. The $14.4 million increase in net loss was primarily due to the increase in the non-cash charge related to the periodic revaluation of warrant liability of $10.2 million and the increase in non-cash stock compensation of $2.7 million.

Licensing revenue decreased by $707,000 to $811,000 for the six months ended June 30, 2013, compared to $1.5 million for the corresponding period of the prior year, because the up-front payment related to the Servier collaboration was fully amortized as of the third quarter of 2012, and therefore no amortized revenue related to this upfront payment was recognized in 2013.

Research and development expenses increased to $10.0 million for the six months ended June 30, 2013, from $8.1 million for the corresponding period of the prior year, primarily as a result of increased activities in Intercept's development program for its product candidate, obeticholic acid (OCA).  The increase in R&D expense includes an increase of $1.3 million in non-cash stock-based compensation for the six months ended June 30, 2013 compared t
'/>"/>

SOURCE Intercept Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
8. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
9. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
10. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Not even geckos and spiders can sit upside down forever. ... have demonstrated this in an article just published in ... industrial benefit. , Geckos and spiders that seem to be ... have fascinated researchers worldwide for many years. We will soon ... same way as the gecko,s foot. But the fact is, ...
(Date:7/10/2014)... University of Illinois at Urbana-Champaign provides new insights ... spin and heat at the nanoscale, and addresses ... data storage and information processing. , "Electrons ... In a typical charge current, electrons, spin-angular-momentum is ... David Cahill, a professor of materials science and ...
(Date:1/15/2014)... akin to assembling a club sandwich at the ... researchers have succeeded in crafting a uniform, multi-walled ... foam commonly used in upholstered furniture and other ... polyurethane foam was reduced 35 percent compared with ...
(Date:1/15/2014)... Ill. , Jan. 15, 2014  Bill Jacobs Automotive, a ... , is teaming up with the Heartland Blood Center and ... blood drive. The drive takes place Saturday, Jan. 18 at ... - 2 p.m. (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  ...
Breaking Biology Technology:Even geckos can lose their grip 2University of Illinois study advances limits for ultrafast nano-devices 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2Join the Bill Jacobs Auto blood drive and receive a free oil change 2
... of Convertible Preferred Stock -, DALLAS, Jan. ... announced today that it has executed agreements,for $2.7 ... into agreements,with institutional and accredited investors to purchase ... the Company,s Series A Convertible,Preferred Stock. This equity ...
... Healionics Corporation, a,provider of tissue regeneration and ... it has raised $1.7 million,in a Series A ... Carl Lombardi, former CEO of SpaceLabs Medical and ... & Rejuvenation Center., "We are pleased to ...
... in cash at year end; no equity financings expected ... disease programs to continue in,2008; latest data for all ... - Expansion of research and development investment ... lysosomal diseases in 2008, CRANBURY, N.J., Jan. 29 ...
Cached Biology Technology:Access Pharmaceuticals Announces $2.7 Million New Equity 2Access Pharmaceuticals Announces $2.7 Million New Equity 3Healionics Corporation Completes Series A Financing 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 11Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 12Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 13Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 14
(Date:7/11/2014)... have explored two different ways that allow unprecedented ... the formation of oxygen molecules in photosynthesis. The ... journal Nature Communications . , "The new ... for water oxidation, which are key components for ... of solar energy in fuels like hydrogen, ethanol ...
(Date:7/11/2014)... under the normal circumstances, astrocytes participate in ... environment, and exhibit therapeutic and repairing effects ... studies have found that nerve cells differentiated ... have reduced viability, which produces influences on ... Kailuan General Hospital, Hebei United University, China ...
(Date:7/10/2014)... In Santa Fe, Albuquerque, and other major cities in ... watered with treated municipal wastewater rather than precious potable ... more than 40% of all golf courses receive treated ... courses. , Additionally, golf courses and homeowners alike ... nutrient in fertilizer is nitrate. A New Mexico State ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2'Tailored' water -- the latest in lawn care 2
... non-native mussels in the Great Lakes has caused ... two of the planet,s largest freshwater lakes, according ... The blitzkrieg advance of two closely related species ... of their life-supporting algae, resulting in a remarkable ...
... 2011 A natural hormone known to inhibit aging can ... researchers have demonstrated. Scientists led by Dr. Makoto Kuro-o, ... hormone Klotho suppressed both renal fibrosis a common complication ... The findings are available online in the Journal of ...
... warming may be the greatest challenge of the present generation. ... the average citizen often wonders what he or she can ... FROM GERMANY,S SUCCESS IN HARNESSING CLEAN ENERGY" (Prometheus Books, $19) ... in the making veteran science and technology journalist Bob ...
Cached Biology News:Invasive mussels causing massive ecological changes in Great Lakes 2Invasive mussels causing massive ecological changes in Great Lakes 3Anti-aging hormone Klotho inhibits renal fibrosis, cancer growth 2Switching to solar 2